Novo Nordisk Plummets 23% as CEO Shakeup Fails to Stem U.S. Sales Slowdown

Novo Nordisk (NASDAQ: NVO) faced a harsh session Tuesday, with shares plunging as much as 26% before closing down 23%. The drop came on the heels of the Danish pharma giant naming a new CEO and slashing its full-year revenue projections on softer-than-expected sales in the U.S. for its flagship weight loss drug Wegovy and diabetes treatment Ozempic.

Maziar Mike Doustdar, a long-time company insider who has been with Novo Nordisk since 1992, is stepping into the CEO role starting August 7, replacing Lars Fruergaard Jørgensen, whose May departure shocked many. Doustdar's track record includes senior roles across Europe and Asia, most recently as EVP of international operations. The chairman, Helge Lund, called him the "best person" to steer Novo Nordisk through what's described as the "next growth phase." Whether that translates into reversing the stock's slide remains to be seen.

The company adjusted its 2025 outlook downward, now forecasting sales growth between 8% and 14%-a sharp fall from the 13%-21% range it had earlier guided. On the profit side, the update sees operating earnings increasing 10% to 16%, down from the prior 16% to 24% target, all figures at constant exchange rates.

The key culprit: weaker sales of Wegovy in the U.S., hit by persistent competition from compounded GLP-1 therapies and a slower-than-anticipated market ramp-up. Novo Nordisk's statement cited the "persistent use of compounded GLP-1s" and its impact on growth, a thorn in the side for the company. This follows a similar warning back in May when the firm posted disappointing Q1 sales numbers. Full Q2 figures are due August 6 and will likely be under the microscope.

This isn't just about Wegovy. Ozempic, another pillar of Novo Nordisk's portfolio, also saw a slowdown. The company has been grappling with a combination of increased competition after an FDA ruling related to drug shortages, and the erosion of market share to cheaper alternatives. The company expects some relief in the second half of the year as copycat drugs' availability starts to decline.

To put this in perspective, Novo Nordisk's stock has shed over 42% year-to-date, making this the toughest stretch in recent memory for the pharmaceutical heavyweight. Adding fuel to the fire, results from trials on its next-gen obesity candidate, CagriSema, have failed to excite the market, amplifying investor skepticism.

All in all, the new CEO walks into a challenging scene. Wegovy's U.S. growth trajectory is cooler than hoped, competitive pressures and regulatory issues muddy the waters, and market doubts linger over future product pipelines. Plenty of questions hang in the air: Can Doustdar reshape the path forward, or is the market settling into a more cautious view of Novo's ambitions?